SCHEMBL6775192

SCHEMBL6775192

CC(C)n1cnc2c(Nc3cccc(NC(=O)C#Cc4ccc(F)cc4)c3)nc(NC3CCC(O)CC3)nc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 9/20 0.54
CCNE1 P24864 5/20 0.48
CDK2 P24941 5/20 0.48
CCNE2 O96020 4/20 0.48
CCNA2 P20248 3/20 0.48
CCNA1 P78396 3/20 0.48
CDK5 Q00535 3/20 0.48
CDK5R1 Q15078 3/20 0.48
FLT3 P36888 1/20 0.48
NPC1 O15118 1/20 0.48
CCNT1 O60563 2/20 0.47
CDK9 P50750 2/20 0.47
CDK7 P50613 1/20 0.47
CCNH P51946 1/20 0.47
CCNT2 O60583 1/20 0.46
CLK1 P49759 4/20 0.46
CLK2 P49760 4/20 0.46
CLK4 Q9HAZ1 4/20 0.46
CDK4 P11802 1/20 0.46
CCNB1 P14635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6770594 0.94 CDK1 (0.55) CDK1CCNE1CDK2CCNE2CCNA2
SCHEMBL6770758 0.94 CDK1 (0.56) CDK1CCNE1CDK2CCNE2CCNA2
SCHEMBL6775328 0.93 CDK1 (0.60) CDK1CCNE1CDK2CCNE2CCNA2
SCHEMBL6770841 0.92 CDK1 (0.55) CDK1CCNE1CDK2CCNE2CCNA2
SCHEMBL6576950 0.89 CDK1 (0.71) CDK1CCNE1CDK2CCNB1
SCHEMBL6576509 0.89 CDK1 (0.71) CDK1CCNE1CDK2CCNB1
SCHEMBL6574743 0.82 CDK1 (0.67) CDK1CCNE1CDK2CCNA2CDK5
SCHEMBL6574741 0.82 CDK1 (0.67) CDK1CCNE1CDK2CCNA2CDK5
SCHEMBL6574902 0.82 CDK1 (0.71) CDK1CCNE1CDK2CCNB1
SCHEMBL6574904 0.82 CDK1 (0.71) CDK1CCNE1CDK2CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6767906-B2 INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. NOVARTIS AG (CH) 2004-07-27 US claimed